Last reviewed · How we verify
NCT03161990
DAIR for Infected Total Hip Arthroplasty - Does the Operative Approach Influence the Functional Result?
trial testing Transgluteal approach to the hip joint in Hip Prosthesis Infection in 226 participants. Completed in 17 November 2018.
17 November 2018
Quick facts
| Lead sponsor | University Hospital, Akershus |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 226 |
| Start date | 23 April 2018 |
| Primary completion | 17 November 2018 |
| Estimated completion | 17 November 2018 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- Transgluteal approach to the hip joint
- Posterior approach to the hip joint
Conditions studied
- Hip Prosthesis Infection — all drugs for Hip Prosthesis Infection →
- Arthroplasty Complications — all drugs for Arthroplasty Complications →
Sponsor
University Hospital, Akershus
Who can join
18 and older, any sex, with Hip Prosthesis Infection or Arthroplasty Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The functional outcome and quality of life after treatment for an infected hip arthroplasty have been found to be significantly worse compared to an uncomplicated arthroplasty. However, the type of revision surgery chosen to treat the infection plays a role for the functional outcome. The concept of DAIR (debridement, antibiotics and implant retention) has been shown to yield god results with respect to infection control in cases of early infection with a stable implant and better functional results than a to-stage revision. In patients where infection control was achieved after just one DAIR procedure the functional outcome was comparable to an uncomplicated primary arthroplasty. However, it is not known if the operative approach used for the primary and revision surgery plays a role for the functional result after treatment of an infected total hip arthroplasty with DAIR. The project's aim is to investigate if the choice of the operative approach (transgluteal or posterior) for the primary hip replacement and the revision surgery has an influence on the functional result after debridement and implant retention for an infected total hip replacement.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Operative approach influences functional outcome after DAIR for infected total hip arthroplasty.
Pollmann CT, Gjertsen JE, Dale H, Straume-Næsheim TM, et al · · 2020 · cited 7× · PMID 33249901 · DOI 10.1302/0301-620x.102b12.bjj-2020-0501.r1
Verify or expand the search:
- PubMed search for NCT03161990
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hip Prosthesis Infection
Currently open trials in the same condition.
- NCT06603831 — Clinical Evaluation and Cost-effectiveness Analysis of 3D Digital Surgery in Traumatology · NA · recruiting
- NCT06527664 — Innovative Technologies for Salvage Procedures of Failed Treatments of Osteoarthritis: Biomimetics Solutions (CustomPN) · recruiting
Other University Hospital, Akershus trials
Trials by the same sponsor.
- NCT06865027 — The Effect of Arterial Carbon Dioxide Levels on Cerebral Blood Flow and Cerebral Autoregulation in the Steep Trendelenbu · NA · enrolling by invitation
- NCT06721754 — Diabetes Related Foot Ulcers with Negative Pressure Wound Therapy · NA · recruiting
- NCT06731985 — The Follow-up After Shorter Tapes Study. Effectiveness and Safety of Shorter Trans-obturator Tapes. · recruiting
- NCT06576752 — Management of Patients with Heart Failure At Home After Hospital Discharge · NA · recruiting
- NCT06032715 — Brief Intervention for Sleep Medication Misuse Among Elderly · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03161990 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Akershus
- Last refreshed: 18 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03161990.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing